Stock AnalizMaravai Lifesciences Holdings, Inc. MRVI
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Maravai Lifesciences Holdings, Inc. (MRVI) is a healthcare company listed in the US with a market value of about $2.0B. In the twelve months to September 30, 2026 it had revenue of $213M and net income of -$66M, a net margin of -30.8%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -8% a year, a 5-year average ROIC of 5%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 95% below the current price.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $213M | $186M | $259M | $289M | $883M | $799M | $284M | $143M |
| Net income | -$66M | -$131M | -$145M | -$119M | $220M | $182M | $89M | -$4M |
| Free cash flow | -$13M | -$71M | -$22M | $61M | $519M | $354M | $127M | $7M |
| EPS (diluted) | $-0.43 | $-0.90 | $-1.05 | $-0.90 | $1.67 | $1.56 | $2.36 | $-0.03 |
| Net margin | -30.8% | -70.4% | -55.9% | -41.2% | 24.9% | 22.8% | 31.3% | -3.1% |
| ROIC | — | -38.7% | -34.9% | -2.5% | 45.2% | 55.0% | 18.6% | 14.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $9.64, 28% above the current price; targets range from $8.00 to $12.00; the consensus rating is “Buy”; expected EPS is $-0.07 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Maravai Lifesciences stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 95% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Maravai Lifesciences pay a dividend?
Not currently.
Is Maravai Lifesciences a good stock to buy?
We do not give buy or sell advice. Maravai Lifesciences scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.